SCHEMBL10319977

SCHEMBL10319977

CN1CCN(C(=O)Nc2ccc(-c3cccc(CN(C)C(=O)CNC(=O)O)c3)cc2)CC1

nearest known ligand 0.64

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 15/20 0.64
KDM4E B2RXH2 2/20 0.55
FAAH O00519 2/20 0.52
POLB P06746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11361774 0.87 AOC3 (0.60) AOC3KDM4EFAAH
SCHEMBL11360633 0.87 AOC3 (0.82) AOC3
SCHEMBL10317130 0.83 AOC3 (0.74) AOC3
SCHEMBL10318279 0.80 AOC3 (0.53) AOC3
SCHEMBL10318831 0.79 AOC3 (0.55) AOC3
SCHEMBL10320484 0.78 AOC3 (0.57) AOC3
SCHEMBL10319776 0.78 AOC3 (0.64) AOC3
SCHEMBL10317043 0.78 AOC3 (0.61) AOC3
SCHEMBL11361430 0.78 AOC3 (1.00) AOC3
SCHEMBL10319191 0.77 AOC3 (0.74) AOC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2479165-B1 GLYCINE COMPOUND ASTELLAS PHARMA INC (JP) 2017-10-25 EP disclosed
US-8802679-B2 Glycine compound ASTELLAS PHARMA INC. (JP) 2014-08-12 US disclosed
EP-2479165-A1 GLYCINE COMPOUND Astellas Pharma Inc. (JP) 2012-07-25 EP disclosed
US-20120184520-A1 GLYCINE COMPOUND ASTELLAS PHARMA INC. (JP) 2012-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184520-A1 GLYCINE COMPOUND SLC5A1, AQP1, VAPB AOC3 894/4885KDM4E 3935/4885FAAH 4043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.